Zura Bio Limited Class A Ordinary Shares

ZURANASDAQ • USD
4.27 USD
↗ 0.71 (19.94%)AT CLOSE (03:59 PM EDT)
4.14
↘ 0.13 (2.97%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
4.14
↘ 0.13 (2.97%)
🔴Market: CLOSED

Zura Bio Limited Class A Ordinary Shares (ZURA) trades at $4.29 per share. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Oct 27, 2026.

Open?$3.57
High?$4.33
Low?$3.41
Prev. Close?$3.56
Volume?5.1M
Avg. Volume?3.8M
VWAP?$3.99
Rel. Volume?1.35x
Bid / Ask
Bid?$4.10 × 1.8K
Ask?$4.19 × 500
Spread?$0.09
Midpoint?$4.15
Valuation & Ratios
Market Cap?341.2M
Shares Out?95.8M
Float?55.1M
Float %?57.5%
P/E Ratio?N/A
P/B Ratio?1.92
EPS?-$1.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Employees
40
Market Cap
341.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-03-21
Address
4225 EXECUTIVE SQUARE
LA JOLLA, CA 92037
Phone: 858-247-0520
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
83
Piotroski F-Score?0/9Weak
Altman Z-Score?10.40Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.74%High
Short Interest?7.0M
Days to Cover?1.5
Free Float55.1M
Avg Daily Volume4.8M
Settlement Date2026-10-15
Financial Health
Current Ratio?11.29Strong
Quick Ratio?11.29Strong
Cash Ratio?11.06Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
76
1.92CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-68.8%WEAK▾
ROA?
S&P
3
-62.8%WEAK▾
Cash Flow & Enterprise
FCF?$-22354395
Enterprise Value?$153.5M
Fundamentals ratios updated end of day